%A Lee,Elizabeth C. %A Cameron,Scott J. %D 2017 %J Frontiers in Cardiovascular Medicine %C %F %G English %K Thrombosis,Platelet Activation,Platelet dysfunction,Cancer Progression,tumor education %Q %R 10.3389/fcvm.2017.00067 %W %L %M %P %7 %8 2017-November-07 %9 Mini Review %+ Scott J. Cameron,Aab Cardiovascular Research Institute,United States,scott_cameron@urmc.rochester.edu %+ Scott J. Cameron,Department of Medicine, Division of Cardiology, University of Rochester School of Medicine,United States,scott_cameron@urmc.rochester.edu %+ Scott J. Cameron,Department of Surgery, Cardiac Surgery, University of Rochester,United States,scott_cameron@urmc.rochester.edu %# %! Dysregulated platelet function in malignancy %* %< %T Cancer and Thrombotic Risk: The Platelet Paradigm %U https://www.frontiersin.org/articles/10.3389/fcvm.2017.00067 %V 4 %0 JOURNAL ARTICLE %@ 2297-055X %X Hematologic malignancies and solid tumors increase the risk of venous and arterial thrombosis and contribute greatly to patient morbidity and mortality. Thrombosis occurs when the intricate balance of circulating antithrombotic and prothrombotic blood elements are disrupted. In recent years, the interplay between paraneoplastic cells and platelets has become apparent, with a change in platelet phenotype causing dysregulated platelet activity. This review discusses mechanism of thrombosis in cancer, evidence for using drug therapy, and exciting research efforts to understand and hopefully control aberrant thrombotic events in patients with cancer.